Skip to Content

Iovance Biotherapeutics Inc IOVA

Morningstar Rating
$11.72 −0.08 (0.68%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

IOVA is trading at a 55% discount.
Price
$11.83
Fair Value
$73.69
Uncertainty
Extreme
1-Star Price
$878.57
5-Star Price
$7.14
Economic Moat
Vltn
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IOVA is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$11.80
Day Range
$11.4711.94
52-Week Range
$3.2118.33
Bid/Ask
$11.61 / $11.86
Market Cap
$3.27 Bil
Volume/Avg
3.7 Mil / 9.6 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
2,333.40
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
557

Comparables

Valuation

Metric
IOVA
NUVL
MRSN
Price/Earnings (Normalized)
Price/Book Value
5.175.9212.30
Price/Sales
2,333.4011.85
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
IOVA
NUVL
MRSN
Quick Ratio
2.5422.623.29
Current Ratio
2.7922.833.36
Interest Coverage
−44.11
Quick Ratio
IOVA
NUVL
MRSN

Profitability

Metric
IOVA
NUVL
MRSN
Return on Assets (Normalized)
−49.22%−19.79%−49.57%
Return on Equity (Normalized)
−63.56%−20.76%−211.52%
Return on Invested Capital (Normalized)
−57.91%−25.56%−146.81%
Return on Assets
IOVA
NUVL
MRSN
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRDjmsfnkblVwnc$553.3 Bil
VRTX
Vertex Pharmaceuticals IncFddcbzyxcFhvczss$101.6 Bil
REGN
Regeneron Pharmaceuticals IncZvbmkmchmKpcbvxv$98.9 Bil
MRNA
Moderna IncTtmbmkqksZsv$39.7 Bil
ARGX
argenx SE ADRPqzqmrwhkHlfn$21.5 Bil
BNTX
BioNTech SE ADRCmrcmzmrrLhrf$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncCdbqjkmkXbrjxg$18.4 Bil
BMRN
Biomarin Pharmaceutical IncRnrrkpyjWhdtb$17.2 Bil
RPRX
Royalty Pharma PLC Class AMtpctklsGrpjjdl$12.3 Bil
INCY
Incyte CorpJlmzycmtLvclbt$11.8 Bil

Sponsor Center